As the landscape of targeted cancer treatment evolves, antibody-drug conjugates (ADCs) have emerged as a cornerstone of ...

A targeted antibody‑drug conjugate shrinks tumors and slows progression in recurrent uterine cancer by ferrying potent ...

A major real-world study by University of California, Irvine pharmacy researchers has found serious blood-related side ...

Read more on antibody drug conjugates in urothelial carcinoma where enfortumab vedotin and disitamab vedotin show high ...

The field of oncology has seen transformative advancements with the development of antibody-drug conjugates (ADCs), which are rapidly revolutionizing the treatment of several cancer types, including ...

Water-soluble polymers conjugated to proteins and anticancer drugs are in routine clinical use and clinical development as both single agents and components of combination therapy. This is ...

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced ...

The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4 th Novel Conjugates Summit ...

Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study Antibody-drug conjugates (ADCs) are ...

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs), developed by longtime partner C4 Therapeutics, staking its claim to an emerging treatment approach in ...

Parabilis is set to receive $125m, including a $50m upfront payment and a $75m investment, subject to agreed conditions.

Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers ADCs have become mainstream therapies ...